NCT00326664已完成1 期
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 55
- 试验地点
- 11
- 主要终点
- Maximum tolerated dose, defined as the dose at which the model estimates that 25% of patients will experience dose-limiting toxicity as measured by NCI CTCAE v4.0
研究概览
简要总结
This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
详细描述
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose of AZD2171 in pediatric patients with recurrent, progressive, or refractory primary CNS tumors.
II. Describe the toxicity profile and dose-limiting toxicities of AZD2171 in these patients.
SECONDARY OBJECTIVES:
I. Characterize inter-patient variability in the pharmacokinetics of AZD2171 in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed primary CNS tumor
- •Histologically benign brain tumors (e.g., low-grade glioma) allowed
- •Histological requirement waived for intrinsic brain stem or diffuse optic pathway tumors, but must have clinical and/or radiographic evidence of progression
- •Recurrent, progressive, or refractory disease
- •Absolute neutrophil count >= 1,000/mm^3 (unsupported)
- •Platelet count >= 75,000/mm^3 (unsupported)
- •Creatinine =< 1.5 times upper limit of normal (ULN) OR glomerular filtration rate >= 70 mL/min
- •Bilirubin =< 1.5 times ULN
- •ALT =< 2.5 times ULN
- •Urine dipstick or urinalysis < 1+ protein
- •Albumin >= 3 g/dL
- •Karnofsky performance status (PS) 60-100% (> 16 years of age) OR Lansky PS 60-100% (=< 16 years of age)
- •Karnofsky/Lansky PS 70-100% for patients at increased risk for compromised LVEF
- •Hemoglobin >= 8 g/dL (transfusion support allowed)
- •No overt renal, hepatic, cardiac, or pulmonary disease
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •QTc prolongation =< 500 msec
- •No other significant ECG abnormality within the past 14 days
- •No clinically significant, unrelated, systemic illness, including serious infections or significant cardiac, pulmonary, hepatic, or other organ dysfunction, that would preclude study participation
- •No uncontrolled hypertension
- •Defined as systolic and diastolic BP > 95th percentile for age (ages 1-17)
- •Defined as BP > 140/90 (ages 18 and older)
- •No New York Heart Association class III or IV disease and Karnofsky/Lansky PS < 70
- •Class II disease controlled with treatment and increased monitoring is allowed
- •Recovered from all prior therapy
- •No prior AZD2171
- •At least 3 weeks since prior myelosuppressive anticancer chemotherapy (6 weeks for nitrosoureas)
- •More than 1 weeks since prior investigational or biologic agents
- •If the investigational or biologic agent has a prolonged half-life (> 48 hours), then these patients must be discussed with the study chair prior to registration
- •No concurrent drugs or biologics with proarrhythmic potential
- •More than 3 months since last fraction of craniospinal radiotherapy or total-body irradiation
- •More than 4 weeks since last fraction of focal irradiation to symptomatic metastatic sites
- •At least 6 months since prior allogeneic bone marrow transplantation
- •At least 3 months since prior autologous bone marrow or stem cell transplantation
- •At least 1 week since prior filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa (2 weeks for pegfilgrastim)
- •No other concurrent investigational agents
- •Concurrent dexamethasone allowed provided patient is on a stable or decreasing dose for ≥ 1 week before study entry
- •No concurrent chemotherapy
- •No concurrent routine use of G-CSF, GM-CSF, or epoetin alfa
- •Able to swallow tablets
- •Any neurologic deficits must be stable for >= 1 week
- •If the investigational or biologic agent has a prolonged half-life (> 48 hours), then these patients must be discussed with the study chair prior to registration
排除标准
- •No known curative therapy available
研究组 & 干预措施
Treatment (cediranib maleate)
Experimental
Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
干预措施: Cediranib Maleate (Drug)
结局指标
主要结局
Maximum tolerated dose, defined as the dose at which the model estimates that 25% of patients will experience dose-limiting toxicity as measured by NCI CTCAE v4.0
时间窗: 42 days
Estimated using the modified Continual Reassessment Method (CRM).
次要结局
未报告次要终点
研究者
研究点 (11)
Loading locations...
相似试验
进行中（未招募）
不适用
AZD2171 in Treating Young Patients With Previousley untreatable Primary CNS TumoursRecurrent, Progressive, or Refactory Primary CNS TumoursEUCTR2012-001154-26-Outside-EU/EEAPediatric Brain Tumour Consortium55
已完成
2 期
AZD2171 in Treating Patients With Recurrent or Stage IV MelanomaAcral Lentiginous Malignant MelanomaCiliary Body and Choroid Melanoma, Medium/Large SizeCiliary Body and Choroid Melanoma, Small SizeExtraocular Extension MelanomaIntraocular MelanomaLentigo Maligna Malignant MelanomaRecurrent MelanomaStage, Intraocular MelanomaStage IV MelanomaSuperficial Spreading Malignant MelanomaIris MelanomaNCT00243061National Cancer Institute (NCI)24
已完成
1 期
A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC)HIV InfectionsNCT00000701National Institute of Allergy and Infectious Diseases (NIAID)12
撤回
1 期
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid LeukemiaCNS 2aCNS 2bCNS 2cCNS1Recurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Myeloid LeukemiaNCT02791919National Cancer Institute (NCI)
已完成
1 期
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaNCT00662506National Cancer Institute (NCI)46